[go: up one dir, main page]

UA107550C2 - Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів - Google Patents

Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів

Info

Publication number
UA107550C2
UA107550C2 UAA201404419A UAA201404419A UA107550C2 UA 107550 C2 UA107550 C2 UA 107550C2 UA A201404419 A UAA201404419 A UA A201404419A UA A201404419 A UAA201404419 A UA A201404419A UA 107550 C2 UA107550 C2 UA 107550C2
Authority
UA
Ukraine
Prior art keywords
preparation
methods
tetraein
carboxamamid
estra
Prior art date
Application number
UAA201404419A
Other languages
English (en)
Russian (ru)
Inventor
Ulrich Bothe
Naomi Barak
Matthias Busemann
Oliver Martin Fischer
Andrea Rotgeri
Isabella Gashaw
Ingo Hartung
Tobias Marquardt
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA107550(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of UA107550C2 publication Critical patent/UA107550C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Винахід належить до інгібіторів AKR1C3 і до способів їх одержання, до їх застосування для лікування та/або профілактики захворювань і також до їх застосування для одержання лікарських засобів для лікування та/або профілактики захворювань, зокрема розладів, що супроводжуються підвищеною кровоточивістю, та ендометріозу.
UAA201404419A 2011-09-29 2012-09-24 Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів UA107550C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011083725A DE102011083725A1 (de) 2011-09-29 2011-09-29 Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
PCT/EP2012/068803 WO2013045407A1 (de) 2011-09-29 2012-09-24 Estra-1,3,5(10),16-tetraen-3-carboxamid-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln

Publications (1)

Publication Number Publication Date
UA107550C2 true UA107550C2 (uk) 2015-01-12

Family

ID=46963705

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201404419A UA107550C2 (uk) 2011-09-29 2012-09-24 Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів

Country Status (43)

Country Link
US (1) US9487554B2 (uk)
EP (1) EP2760878B1 (uk)
JP (1) JP5791810B2 (uk)
KR (1) KR20140069013A (uk)
CN (1) CN103827133B (uk)
AP (1) AP2014007598A0 (uk)
AR (1) AR088180A1 (uk)
AU (1) AU2012314627B2 (uk)
BR (1) BR112014007223A2 (uk)
CA (1) CA2850047C (uk)
CL (1) CL2014000775A1 (uk)
CO (1) CO6920294A2 (uk)
CR (1) CR20140144A (uk)
CU (1) CU20140037A7 (uk)
CY (1) CY1117123T1 (uk)
DE (1) DE102011083725A1 (uk)
DK (1) DK2760878T3 (uk)
DO (1) DOP2014000059A (uk)
EA (1) EA025518B9 (uk)
EC (1) ECSP14013275A (uk)
ES (1) ES2560257T3 (uk)
GT (1) GT201400059A (uk)
HK (1) HK1197414A1 (uk)
HR (1) HRP20160050T1 (uk)
HU (1) HUE026645T2 (uk)
IL (1) IL231755A (uk)
JO (1) JO3122B1 (uk)
MA (1) MA35455B1 (uk)
MX (1) MX2014003823A (uk)
MY (1) MY175804A (uk)
PE (1) PE20141554A1 (uk)
PH (1) PH12014500674A1 (uk)
PL (1) PL2760878T3 (uk)
PT (1) PT2760878E (uk)
RS (1) RS54521B1 (uk)
SG (1) SG11201400144SA (uk)
SI (1) SI2760878T1 (uk)
TN (1) TN2014000131A1 (uk)
TW (1) TWI537284B (uk)
UA (1) UA107550C2 (uk)
UY (1) UY34356A (uk)
WO (1) WO2013045407A1 (uk)
ZA (1) ZA201401568B (uk)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150036319A (ko) * 2012-07-10 2015-04-07 바이엘 파마 악티엔게젤샤프트 3-치환된 에스트라-1,3,5(10),16-테트라엔 유도체, 그의 제조방법, 이를 포함하는 약학 제제 및 의약품 제조를 위한 그의 용도
SG11201505875WA (en) * 2013-02-21 2015-09-29 Bayer Pharma AG Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3)
ES2696848T3 (es) * 2014-09-11 2019-01-18 Bayer Pharma AG Inhibidores de oestra-1,3,5(10),16-tetraeno AKR1C3 sustituido con 3-nitrógeno o azufre
US10167293B2 (en) 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (en) * 2016-07-11 2018-01-17 Bayer Pharma Aktiengesellschaft Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases
CA3047196A1 (en) 2016-12-19 2018-06-28 Bayer Pharma Aktiengesellschaft [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
US20200087284A1 (en) 2016-12-19 2020-03-19 Bayer Pharma Aktiengesellschaft [4-(phenylsulfonyl)piperazin-1-yl](1h-1, 2, 3-triazol-4-yl)methanones
TW201825478A (zh) 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
EP3421483A1 (en) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
CN108503695B (zh) * 2018-03-09 2021-06-08 南方医科大学南方医院 基于GnRH多肽衍生物的示踪剂及其制备方法和应用
CN110693892A (zh) * 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
BR112021017377A2 (pt) 2019-03-06 2021-11-16 Propella Therapeutics Inc Pró-fármacos de abiraterona
CN113683648A (zh) * 2021-08-26 2021-11-23 上海皓鸿生物医药科技有限公司 一种2’-氟-2’-脱氧尿苷的合成方法及其中间体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632003A (en) 1985-07-15 1986-12-30 Kopp William L Musical instrument sound quality enhancement device
KR100235135B1 (ko) * 1992-03-31 2000-01-15 말콤 카터 암치료에 유용한 17-치환된 스테로이드
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
AU2707999A (en) * 1998-03-11 1999-09-27 Endorecherche Inc. Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
EP1756139A4 (en) 2004-03-12 2009-07-29 Entremed Inc ANTI-ANGIOGENIC AGENTS
JP5264760B2 (ja) * 2006-11-30 2013-08-14 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング １７β−ＨＳＤインヒビターとしての置換エストラトリエン誘導体
WO2009120565A2 (en) 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
MY162934A (en) 2010-04-27 2017-07-31 Pharma Mar Sa Anticancer steroidal lactones unsaturated in position 7 (8)

Also Published As

Publication number Publication date
EP2760878B1 (de) 2015-10-28
CL2014000775A1 (es) 2014-08-18
US9487554B2 (en) 2016-11-08
AR088180A1 (es) 2014-05-14
EP2760878A1 (de) 2014-08-06
CY1117123T1 (el) 2017-04-05
TN2014000131A1 (en) 2015-07-01
JP5791810B2 (ja) 2015-10-07
CA2850047A1 (en) 2013-04-04
IL231755A (en) 2016-06-30
AP2014007598A0 (en) 2014-04-30
KR20140069013A (ko) 2014-06-09
CO6920294A2 (es) 2014-04-10
PL2760878T3 (pl) 2016-04-29
BR112014007223A2 (pt) 2017-04-04
HK1197414A1 (zh) 2015-01-16
DE102011083725A1 (de) 2013-04-04
WO2013045407A1 (de) 2013-04-04
PE20141554A1 (es) 2014-10-24
TWI537284B (zh) 2016-06-11
JO3122B1 (ar) 2017-09-20
CN103827133B (zh) 2015-11-25
SG11201400144SA (en) 2014-05-29
AU2012314627B2 (en) 2016-08-18
PH12014500674A1 (en) 2021-08-09
TW201317253A (zh) 2013-05-01
CR20140144A (es) 2014-05-16
CN103827133A (zh) 2014-05-28
HRP20160050T1 (hr) 2016-02-12
DK2760878T3 (en) 2016-01-25
MY175804A (en) 2020-07-09
CU20140037A7 (es) 2014-07-30
GT201400059A (es) 2015-02-17
CA2850047C (en) 2016-03-29
JP2014527994A (ja) 2014-10-23
PT2760878E (pt) 2016-02-26
DOP2014000059A (es) 2014-06-15
NZ622081A (en) 2015-10-30
EA201490653A1 (ru) 2014-09-30
SI2760878T1 (sl) 2016-02-29
EA025518B1 (ru) 2016-12-30
ES2560257T3 (es) 2016-02-18
US20140249119A1 (en) 2014-09-04
UY34356A (es) 2013-04-30
MA35455B1 (fr) 2014-09-01
ECSP14013275A (es) 2014-04-30
HUE026645T2 (en) 2016-07-28
ZA201401568B (en) 2016-11-30
AU2012314627A1 (en) 2014-04-10
RS54521B1 (en) 2016-06-30
MX2014003823A (es) 2014-06-04
EA025518B9 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
WO2014062720A3 (en) Methods of treating cancer
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
HUE053113T2 (hu) Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra
GB201118656D0 (en) New compounds
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
UY33219A (es) Cetoenoles cíclicos para terapias
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
TH145100A (th) อนุพันธ์เอสทรา-1,3,5(10),16-เททระอีน-3-คาร์บอกซาไมด์ (Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives), กรรมวิธีสำหรับการเตรียมอนุพันธ์เหล่านั้น, ยาเตรียมทางเภสัชกรรมที่ประกอบรวมด้วยอนุพันธ์เหล่านั้น และการใช้อนุพันธ์เหล่านั้นสำหรับเตรียมเภสัชภัณฑ์
IN2013MU03429A (uk)